Enbrel, Humira & Stelara efficacy and adverse event study

[Fred]

his study looked at the efficacy and adverse events in Enbrel (etanercept), Humira (dalimumab) & Stelara (ustekinumab).

Quote:

---

Background and objectives:
Widely used in the treatment of psoriasis, biologics have been tested in numerous clinical trials. However, drug efficacies and adverse events (AEs) may differ in ‘real-world’ patients as they do not undergo as rigorous selection and monitoring. Our objective was to examine drug survival, efficacy, and AEs (quality, time of onset) in ‘real-world’ psoriasis patients treated with etanercept, adalimumab, and ustekinumab.

Patients and methods:
Retrospective data analysis (Jan 1, 2004 to Jun 30, 2015) of patients treated at a psoriasis clinic in an Austrian hospital. All patients who had received at least one dose of etanercept, adalimumab, or ustekinumab were included in the analysis. We analyzed: demographics, drug survival, Psoriasis Area and Severity Index (PASI), as well as quality and time of onset of AEs.

Results:
In 209 treatment series, the estimated median drug survival varied among the various treatments: 21 months (SE: 6.9) for etanercept, 61 months (SE: 9.4) for adalimumab, and 65 months (SE 1.4) for ustekinumab. Male gender and pretreatment with a biologic were positive predictors of longer drug survival in adalimumab. We found no significant difference in drug efficacy as determined by PASI.

Conclusions:
Most AEs occur during the first year of treatment. Adalimumab and ustekinumab are marked by longer drug survival compared to etanercept.

Source: onlinelibrary.wiley.com

*Ealry view funding unknown

[Caroline]

his study looked at the efficacy and adverse events in Enbrel (etanercept), Humira (dalimumab) & Stelara (ustekinumab).

Quote:

---

Background and objectives:
Widely used in the treatment of psoriasis, biologics have been tested in numerous clinical trials. However, drug efficacies and adverse events (AEs) may differ in ‘real-world’ patients as they do not undergo as rigorous selection and monitoring. Our objective was to examine drug survival, efficacy, and AEs (quality, time of onset) in ‘real-world’ psoriasis patients treated with etanercept, adalimumab, and ustekinumab.

Patients and methods:
Retrospective data analysis (Jan 1, 2004 to Jun 30, 2015) of patients treated at a psoriasis clinic in an Austrian hospital. All patients who had received at least one dose of etanercept, adalimumab, or ustekinumab were included in the analysis. We analyzed: demographics, drug survival, Psoriasis Area and Severity Index (PASI), as well as quality and time of onset of AEs.

Results:
In 209 treatment series, the estimated median drug survival varied among the various treatments: 21 months (SE: 6.9) for etanercept, 61 months (SE: 9.4) for adalimumab, and 65 months (SE 1.4) for ustekinumab. Male gender and pretreatment with a biologic were positive predictors of longer drug survival in adalimumab. We found no significant difference in drug efficacy as determined by PASI.

Conclusions:
Most AEs occur during the first year of treatment. Adalimumab and ustekinumab are marked by longer drug survival compared to etanercept.

Source: onlinelibrary.wiley.com

*Ealry view funding unknown

Isn't that a bit strange concerning eternacept? I read an article on an investigation in NL a comparison of eternacept and infliximab, and that showed that with eternacept, there exists no tendency to build up anti-bodies, which basically means that it can be used for a very long period, whithout having to stop using it.
The research was done at AMC hospital together with 5 other medical centres in NL.

[mataribot]

Most of the failures are because of dosing. When the drug is prescribed for RA, there's room for variable dosing. Would be interesting to compare the two.